The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy.
Anti-tumour necrosis factor antagonists have appreciably improved patient outcomes in Crohn's disease, shifting the goals of treatment from control of symptoms to clinical remission (Crohn's disease activity index <150) combined with mucosal healing - the new concept of 'deep r...
मुख्य लेखकों: | Travis, S, Feagan, BG, Rutgeerts, P, van Deventer, S |
---|---|
स्वरूप: | Journal article |
भाषा: | English |
प्रकाशित: |
2012
|
समान संसाधन
-
Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.
द्वारा: Gottlieb, K, और अन्य
प्रकाशित: (2015) -
Central Endoscopy Reading in Inflammatory Bowel Diseases
द्वारा: Panés, J, और अन्य
प्रकाशित: (2016) -
Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials
द्वारा: Feagan, BG, और अन्य
प्रकाशित: (2018) -
The use of oral topically acting glucocorticosteroids in the treatment of
inflammatory bowel disease
द्वारा: P. Rutgeerts
प्रकाशित: (1998-01-01) -
Dysplasia in Inflammatory Bowel Diseases: Definition and Clinical Impact
द्वारा: Karel Geboes, और अन्य
प्रकाशित: (1999-01-01)